Merck & Co., Inc. (NYSE:MRK) Shares Sold by Peregrine Asset Advisers Inc.

Peregrine Asset Advisers Inc. reduced its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 33.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,235 shares of the company’s stock after selling 7,264 shares during the period. Peregrine Asset Advisers Inc.’s holdings in Merck & Co., Inc. were worth $1,878,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Kennedy Capital Management LLC grew its holdings in shares of Merck & Co., Inc. by 16.7% during the third quarter. Kennedy Capital Management LLC now owns 12,573 shares of the company’s stock worth $1,294,000 after buying an additional 1,795 shares in the last quarter. Harbour Investments Inc. grew its holdings in shares of Merck & Co., Inc. by 1.4% during the third quarter. Harbour Investments Inc. now owns 19,716 shares of the company’s stock worth $2,030,000 after buying an additional 265 shares in the last quarter. Financial Gravity Asset Management Inc. grew its holdings in shares of Merck & Co., Inc. by 963.7% during the third quarter. Financial Gravity Asset Management Inc. now owns 4,106 shares of the company’s stock worth $423,000 after buying an additional 3,720 shares in the last quarter. Revisor Wealth Management LLC purchased a new stake in shares of Merck & Co., Inc. during the third quarter worth $229,000. Finally, Resources Management Corp CT ADV grew its holdings in shares of Merck & Co., Inc. by 13.8% in the third quarter. Resources Management Corp CT ADV now owns 19,441 shares of the company’s stock valued at $2,001,000 after purchasing an additional 2,362 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Up 0.2 %

Shares of Merck & Co., Inc. stock opened at $126.08 on Wednesday. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $134.63. The company has a 50 day moving average of $128.99 and a 200 day moving average of $125.39. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $319.34 billion, a P/E ratio of 140.09, a P/E/G ratio of 2.43 and a beta of 0.38.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its quarterly earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.21 billion. During the same quarter in the previous year, the firm earned $1.40 earnings per share. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. As a group, research analysts forecast that Merck & Co., Inc. will post 8.62 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, July 8th. Shareholders of record on Monday, June 17th were issued a dividend of $0.77 per share. The ex-dividend date was Monday, June 17th. This represents a $3.08 dividend on an annualized basis and a yield of 2.44%. Merck & Co., Inc.’s payout ratio is currently 342.22%.

Analyst Ratings Changes

MRK has been the subject of several recent analyst reports. Argus upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, June 5th. Truist Financial raised their price objective on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. Wells Fargo & Company raised their price objective on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 price target on shares of Merck & Co., Inc. in a research report on Tuesday, June 18th. Finally, Berenberg Bank lifted their price target on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a research report on Monday, April 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average target price of $133.00.

Get Our Latest Stock Report on Merck & Co., Inc.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Further Reading

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.